As South Africa becomes the ninth African country to introduce the use of new long-acting drug lenacapavir for HIV prevention, RFI spoke with infectious disease specialist Ndong Essomba Bitchoka about how the treatment works, whether the supply will meet demand and why developing an HIV vaccine remains a challenge. New long-acting antiretroviral treatment lenacapavir requires…
Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite repeated requests. In an open letter, the group renewed its repeated requests to California-based Gilead to sell the drug, saying the company is blocking lenacapavir’s rollout. MSF said it had sought to purchase…
Geneva — A pivotal moment in the fight to end AIDS — ensuring lifesaving innovation reaches those who need it most, wherever they live The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced it has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV…
